<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='/w/ProjectMundo-Anon-106A/style/jats-html.xsl'?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41598
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41598.2045-2322
   </journal-id>
   <journal-title-group>
    <journal-title>
     Scientific Reports
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Sci Rep
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2045-2322
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41598-023-51013-3
   </article-id>
   <article-id pub-id-type="manuscript">
    51013
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41598-023-51013-3
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/4019
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/617
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/617/375/1370/534
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     合并使用抗凝剂和抗血小板药物对非瓣膜性房颤和系统性动脉粥样硬化患者中风后结局的影响
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" id="Au1">
     <name name-style="western">
      <surname>
       Heo
      </surname>
      <given-names>
       JoonNyung
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <name name-style="western">
      <surname>
       Lee
      </surname>
      <given-names>
       Hyungwoo
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Lee
      </surname>
      <given-names>
       Il Hyung
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Lim
      </surname>
      <given-names>
       In Hwan
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <name name-style="western">
      <surname>
       Hong
      </surname>
      <given-names>
       Soon-Ho
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <name name-style="western">
      <surname>
       Shin
      </surname>
      <given-names>
       Joonggyeong
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <name name-style="western">
      <surname>
       Nam
      </surname>
      <given-names>
       Hyo Suk
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <contrib contrib-type="author" corresp="yes" id="Au8">
     <name name-style="western">
      <surname>
       Kim
      </surname>
      <given-names>
       Young Dae
      </given-names>
     </name>
     <address>
      <email>
       neuro05@yuhs.ac
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs41598023510133_cor8">
      h
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01wjejq96
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.15444.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0470 5454
      </institution-id>
      <institution content-type="org-division">
       Department of Neurology
      </institution>
      <institution content-type="org-name">
       Yonsei University College of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Seoul
     </addr-line>
     <country country="KR">
      South Korea
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01wjejq96
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.15444.30
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0470 5454
      </institution-id>
      <institution content-type="org-division">
       Department of Radiology
      </institution>
      <institution content-type="org-name">
       Yonsei University College of Medicine
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Seoul
     </addr-line>
     <country country="KR">
      South Korea
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs41598023510133_cor8">
     <label>
      h
     </label>
     <email>
      neuro05@yuhs.ac
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     3
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    14
   </volume>
   <issue seq="305">
    1
   </issue>
   <elocation-id>
    304
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      29
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      4
     </day>
     <month>
      4
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      29
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      3
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © The Author(s) 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     The Author(s)
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     摘要
    </title>
    <p id="Par1">
     本研究旨在调查在合并动脉粥样硬化疾病和非瓣膜性房颤（NVAF）的患者中，使用抗血小板和抗凝剂（OAC + 抗血小板）与仅使用抗凝剂（OAC）治疗的患者在中风后一年结局是否存在差异。这是一项使用前瞻性队列的回顾性研究，研究对象为连续的缺血性中风患者。根据出院时的用药情况，将合并动脉粥样硬化疾病和NVAF的患者分配到OAC + 抗血小板组或OAC组。比较了在中风后1年内的全因死亡率、复发性缺血性中风、出血性中风、心肌梗死和出血事件。在本研究中，共纳入445名患者，其中149名（33.5%）接受了OAC + 抗血小板治疗。两组之间的所有结局均无显著差异。经过逆概率加权后，OAC + 抗血小板与较低的全因死亡风险（风险比0.48；95%置信区间0.23–0.98；P = 0.045）和心肌梗死（0% vs. 3.0%，P &lt; 0.001）相关。出血性中风的风险无显著差异（P = 0.123）。在NVAF和系统性动脉粥样硬化疾病患者中，OAC + 抗血小板与降低的全因死亡和心肌梗死风险相关，但缺血性中风风险增加。
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1102">
      Cardiorespiratory Medicine and Haematology
     </kwd>
    </nested-kwd>
   </kwd-group>
   <funding-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Yonsei University College of Medicine
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        http://dx.doi.org/10.13039/501100008005
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      6-2022-0170
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Kim
       </surname>
       <given-names>
        Young Dae
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
    <award-group>
     <funding-source>
      <institution-wrap>
       <institution>
        Korea Health Industry Development Institute
       </institution>
       <institution-id institution-id-type="doi" vocab="open-funder-registry">
        http://dx.doi.org/10.13039/501100003710
       </institution-id>
      </institution-wrap>
     </funding-source>
     <award-id award-type="FundRef grant">
      RS-2023-00265497
     </award-id>
     <principal-award-recipient>
      <name name-style="western">
       <surname>
        Kim
       </surname>
       <given-names>
        Young Dae
       </given-names>
      </name>
     </principal-award-recipient>
    </award-group>
   </funding-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      305
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      29
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41598_2023_Article_51013.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1">
   <title>
    引言
   </title>
   <p id="Par2">
    非瓣膜性房颤（NVAF）是缺血性中风最常见的心源性栓塞来源
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    。它显著增加中风的风险，并且由NVAF引起的中风后果比任何其他中风病因都要糟糕
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    。为了预防包括缺血性中风在内的全身性栓塞，强烈建议NVAF患者使用口服抗凝剂（OAC），如维生素K拮抗剂（VKA）或直接口服抗凝剂（DOAC）
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    。
   </p>
   <p id="Par3">
    在NVAF患者中，脑、心脏和外周动脉的全身性动脉粥样硬化可以共存
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
     ,
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
     ,
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    。此外，NVAF中风患者中任何全身性动脉粥样硬化的共存会在相同或不同的血管床中带来更高的血管事件风险，这表明这些患者需要最佳的抗血栓策略
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    。在OAC中加入抗血小板药物可能是管理这些患者的一种选择，尽管这些方案可能会导致出血风险增加
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
     ,
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    。最近的研究表明，低剂量利伐沙班与阿司匹林联合使用可以改善冠状动脉阻塞性疾病（CAOD）或外周动脉阻塞性疾病（PAOD）患者的心血管结局，这表明OAC与抗血小板药物的联合使用可能对管理伴有中风和NVAF的动脉粥样硬化疾病有益。然而，对于NVAF中风和合并全身性动脉粥样硬化的最佳管理，包括颅内或颅外动脉狭窄以及CAOD或PAOD的信息有限
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
     ,
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    。
   </p>
   <p id="Par4">
    本研究旨在调查抗血小板药物与OAC联合使用是否会影响NVAF和全身性动脉粥样硬化患者在初次中风后1年内的结局。
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    结果
   </title>
   <sec id="Sec3">
    <title>
     研究人群
    </title>
    <p id="Par5">
     在6912名缺血性中风或短暂性脑缺血发作（TIA）患者中，选择了1353名先前或新诊断为NVAF的患者。在排除51名（3.8%）住院期间死亡的患者、60名（4.4%）失访的患者、546名（40.3%）没有动脉粥样硬化疾病证据的患者、223名（16.5%）未开抗凝药的患者和28名（2.0%）患有活动性癌症的患者后，本研究纳入了445名患者（Fig.
     <xref ref-type="fig" rid="Fig1">
      1
     </xref>
     ）。
     <fig id="Fig1" position="float">
      <label>
       Figure 1
      </label>
      <caption xml:lang="en">
       <p>
        本研究中纳入患者的流程图。
       </p>
      </caption>
      <graphic href="/w/ProjectMundo-Anon-106A/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig1_HTML.png" id="MO1" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
   <sec id="Sec4">
    <title>
     基线特征
    </title>
    <p id="Par6">
     纳入的445名患者的中位年龄为75岁（四分位距，IQR 70.0–80.0），其中59.3%（n = 264）为男性。在这些患者中，193名（43.4%）患有脑动脉粥样硬化，278名（62.5%）患有CAOD，13名（2.9%）患有PAOD，74名（16.6%）患有主动脉弓粥样硬化，62名（13.9%）植入了冠状动脉支架，12名（2.7%）植入了脑动脉支架。有293名（65.8%）患者在一个动脉床上有动脉粥样硬化病变，121名（27.2%）在两个动脉床上，27名（6.1%）在三个动脉床上，四名（0.9%）在四个动脉床上（Fig.
     <xref ref-type="fig" rid="Fig2">
      2
     </xref>
     和补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ）。
     <fig id="Fig2" position="float">
      <label>
       Figure 2
      </label>
      <caption xml:lang="en">
       <p>
        每种动脉粥样硬化疾病的患者分布。
        <italic>
         CAOD
        </italic>
        冠状动脉闭塞性疾病，
        <italic>
         PAOD
        </italic>
        外周动脉闭塞性疾病。
       </p>
      </caption>
      <graphic href="/w/ProjectMundo-Anon-106A/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig2_HTML.png" id="MO2" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
    <p id="Par7">
     有296名（66.5%）患者仅使用OAC，149名（33.5%）使用OAC + 抗血小板药物。在仅使用OAC的296名患者中，103名（34.8%）接受了VKA，193名（65.2%）接受了DOAC。在接受OAC + 抗血小板药物的149名患者中，96.6%（n = 144）接受了单一抗血小板药物。阿司匹林是最常开具的抗血小板药物（n = 65, 43.6%），其次是氯吡格雷（n = 63, 42.3%），曲克芦丁（n = 11, 7.4%），西洛他唑（n = 5, 3.4%），以及两种抗血小板药物的组合（n = 5, 3.4%）。在OAC + 抗血小板药物组中，VKA的开具频率高于DOAC（55.0% [82/149]为VKA，45.0% [67/149]为DOAC）。在接受VKA的患者中，两组出院时的国际标准化比率没有差异（仅OAC组为2.3 [IQR 1.9–2.7]，OAC + 抗血小板药物组为2.4 [IQR 1.9–2.8]，P = 0.585）。在260名接受DOAC的患者中，10%（n = 26）使用了不足剂量的DOAC，接受不足剂量的患者比例在两组之间没有差异（仅OAC组为10.4% [20/193]，OAC + 抗血小板药物组为9.0% [6/67]，P = 0.925）。出院时97.3%（n = 433）开具了他汀类药物。此外，两组之间的他汀类药物治疗没有差异（仅OAC组为98.0% [290/296]，OAC + 抗血小板药物组为96.0% [143/149]，P = 0.358）。根据急性中风治疗的Org 10,172试验，两组之间的中风亚型没有显著差异（P = 0.137，补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      2
     </xref>
     ）。两种原因以上的亚型是两组中最常见的病因。63.4%（n = 282）的患者进行了经食道超声心动图检查，两组之间没有差异（仅OAC组为65.2% [193/296]，OAC + 抗血小板药物组为59.7% [89/149]，P = 0.305）。当我们使用医疗记录审查和/或电子处方代码评估38名患者的抗血栓方案维持情况时，这些患者在随访期间死亡时可以检查处方信息，出院时的抗血栓方案在81.6%（n = 31）的患者中得以维持。
    </p>
    <p id="Par8">
     与仅使用OAC相比，接受OAC + 抗血小板治疗的患者更可能患有高血压、冠状动脉阻塞性疾病（CAOD）以及脑和冠状动脉支架（表
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     ）。调整这四个变量的多变量逻辑回归分析显示，CAOD（比值比 [OR] 1.71；95% 置信区间 [CI] 1.09–2.69；P = 0.019）、脑支架（OR 5.31；95% CI 1.51–18.60；P = 0.009）和冠状动脉支架（OR 6.24；95% CI 3.42–11.39；P &lt; 0.001）是使用OAC + 抗血小板的独立决定因素。
     <table-wrap id="Tab1">
      <label>
       Table 1
      </label>
      <caption xml:lang="en">
       <p>
        抗血小板和抗凝剂联合使用与单独使用抗凝剂患者基线特征比较
        <bold>
         。
        </bold>
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" rowspan="2"/>
         <th align="left" colspan="3">
          <p>
           未调整组
          </p>
         </th>
         <th align="left" colspan="3">
          <p>
           调整后组
          </p>
         </th>
        </tr>
        <tr>
         <th align="left">
          <p>
           OAC + 抗血小板
          </p>
          <p>
           (n = 149)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 296)
          </p>
         </th>
         <th align="left">
          <p>
           D (%)
          </p>
         </th>
         <th align="left">
          <p>
           OAC + 抗血小板
          </p>
          <p>
           (n = 152.2)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 284.5)
          </p>
         </th>
         <th align="left">
          <p>
           D (%)
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           年龄（&gt; 75 岁）
          </p>
         </td>
         <td align="left">
          <p>
           76 (51.0)
          </p>
         </td>
         <td align="left">
          <p>
           131 (44.3)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           13.5
          </p>
         </td>
         <td align="left">
          <p>
           67.0 (44.0)
          </p>
         </td>
         <td align="left">
          <p>
           127.7 (44.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           性别（男性）
          </p>
         </td>
         <td align="left">
          <p>
           94 (63.1)
          </p>
         </td>
         <td align="left">
          <p>
           170 (57.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           11.5
          </p>
         </td>
         <td align="left">
          <p>
           86.1 (56.5)
          </p>
         </td>
         <td align="left">
          <p>
           167.7 (59.0)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           4.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           高血压
          </p>
         </td>
         <td align="left">
          <p>
           135 (90.6)
          </p>
         </td>
         <td align="left">
          <p>
           246 (83.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           22.3
          </p>
         </td>
         <td align="left">
          <p>
           128.3 (84.3)
          </p>
         </td>
         <td align="left">
          <p>
           243.1 (85.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           糖尿病
          </p>
         </td>
         <td align="left">
          <p>
           60 (40.3)
          </p>
         </td>
         <td align="left">
          <p>
           105 (35.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           9.9
          </p>
         </td>
         <td align="left">
          <p>
           57.8 (38.0)
          </p>
         </td>
         <td align="left">
          <p>
           109.4 (38.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           血脂异常
          </p>
         </td>
         <td align="left">
          <p>
           65 (22.0)
          </p>
         </td>
         <td align="left">
          <p>
           33 (22.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.5
          </p>
         </td>
         <td align="left">
          <p>
           37.8 (24.8)
          </p>
         </td>
         <td align="left">
          <p>
           63.9 (22.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           5.6
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           冠状动脉阻塞性疾病 (CAOD)
          </p>
         </td>
         <td align="left">
          <p>
           106 (71.1)
          </p>
         </td>
         <td align="left">
          <p>
           172 (58.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           27.4
          </p>
         </td>
         <td align="left">
          <p>
           94.3 (62.)
          </p>
         </td>
         <td align="left">
          <p>
           178.2 (62.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           外周动脉阻塞性疾病 (PAOD)
          </p>
         </td>
         <td align="left">
          <p>
           3 (2.0)
          </p>
         </td>
         <td align="left">
          <p>
           10 (3.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           8.4
          </p>
         </td>
         <td align="left">
          <p>
           2.6 (1.7)
          </p>
         </td>
         <td align="left">
          <p>
           5.6 (2.0)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.0
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           当前吸烟者
          </p>
         </td>
         <td align="left">
          <p>
           22 (14.8)
          </p>
         </td>
         <td align="left">
          <p>
           38 (12.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           5.6
          </p>
         </td>
         <td align="left">
          <p>
           18.0 (11.8)
          </p>
         </td>
         <td align="left">
          <p>
           36.3 (12.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.8
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           慢性心力衰竭 (CHF)
          </p>
         </td>
         <td align="left">
          <p>
           17 (11.4)
          </p>
         </td>
         <td align="left">
          <p>
           20 (6.8)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           16.2
          </p>
         </td>
         <td align="left">
          <p>
           13.0 (8.5)
          </p>
         </td>
         <td align="left">
          <p>
           24.1 (8.5)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.2
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           脑支架
          </p>
         </td>
         <td align="left">
          <p>
           8 (5.4)
          </p>
         </td>
         <td align="left">
          <p>
           4 (1.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           22.4
          </p>
         </td>
         <td align="left">
          <p>
           3.3 (2.2)
          </p>
         </td>
         <td align="left">
          <p>
           5.4 (1.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.9
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           冠状动脉支架
          </p>
         </td>
         <td align="left">
          <p>
           44 (29.5)
          </p>
         </td>
         <td align="left">
          <p>
           18 (6.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           64.2
          </p>
         </td>
         <td align="left">
          <p>
           19.9 (13.1)
          </p>
         </td>
         <td align="left">
          <p>
           33.7 (11.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           初始NIHSS（&gt; 4）
          </p>
         </td>
         <td align="left">
          <p>
           74 (49.7)
          </p>
         </td>
         <td align="left">
          <p>
           146 (49.3)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.7
          </p>
         </td>
         <td align="left">
          <p>
           77.5 (50.9)
          </p>
         </td>
         <td align="left">
          <p>
           141.1 (49.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.7
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           低GFR
          </p>
         </td>
         <td align="left">
          <p>
           6 (4.0)
          </p>
         </td>
         <td align="left">
          <p>
           7 (2.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           9.4
          </p>
         </td>
         <td align="left">
          <p>
           4.9 (3.2)
          </p>
         </td>
         <td align="left">
          <p>
           10.3 (3.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.3
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           脑动脉狭窄
          </p>
         </td>
         <td align="left">
          <p>
           70 (47.0)
          </p>
         </td>
         <td align="left">
          <p>
           123 (41.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           10.9
          </p>
         </td>
         <td align="left">
          <p>
           67.2 (44.1)
          </p>
         </td>
         <td align="left">
          <p>
           120.6 (42.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           3.5
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           主动脉粥样硬化
          </p>
         </td>
         <td align="left">
          <p>
           24 (16.1)
          </p>
         </td>
         <td align="left">
          <p>
           50 (16.9)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.1
          </p>
         </td>
         <td align="left">
          <p>
           22.2 (14.6)
          </p>
         </td>
         <td align="left">
          <p>
           42.9 (15.1)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           1.4
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           高剂量他汀
          </p>
         </td>
         <td align="left">
          <p>
           102 (68.5)
          </p>
         </td>
         <td align="left">
          <p>
           226 (76.4)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           17.7
          </p>
         </td>
         <td align="left">
          <p>
           111.8 (73.4)
          </p>
         </td>
         <td align="left">
          <p>
           212.3 (74.6)
          </p>
         </td>
         <td align="char" char=".">
          <p>
           2.6
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        数值以数量（%）表示分类变量，以中位数[四分位数范围]表示连续变量。
       </p>
       <p>
        <italic>
         CAOD
        </italic>
        冠状动脉阻塞性疾病,
        <italic>
         PAOD
        </italic>
        外周动脉阻塞性疾病,
        <italic>
         CHF
        </italic>
        慢性心力衰竭,
        <italic>
         NIHSS
        </italic>
        美国国立卫生研究院卒中量表,
        <italic>
         GFR
        </italic>
        肾小球滤过率。
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec5">
    <title>
     原始研究人群的结局比较
    </title>
    <p id="Par9">
     在1年的随访期间（中位数，365天；IQR 321–365天），一年内的综合结局发生在93名（20.9%）患者中。对于每个结局，50名（11.2%）患者发生全因死亡，16名（2.9%）患者发生复发性缺血性中风（3名[0.7%]致命和13名[2.9%]非致命），5名（1.1%）患者发生心肌梗死（3名[0.7%]致命和2名[0.4%]非致命），4名（0.9%，均为非致命）患者发生出血性中风，35名（7.9%）患者发生出血事件（1名[0.2%]致命和34名[7.6%]非致命）。抗栓治疗方案之间的所有预定结局发生率没有差异（表
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ）。
     <table-wrap id="Tab2">
      <label>
       Table 2
      </label>
      <caption xml:lang="en">
       <p>
        口服抗凝剂与抗血小板联合使用对结果的风险比。
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <thead>
        <tr>
         <th align="left" rowspan="2"/>
         <th align="left" colspan="4">
          <p>
           未调整组
          </p>
         </th>
         <th align="left" colspan="4">
          <p>
           调整后组
          </p>
         </th>
        </tr>
        <tr>
         <th align="left">
          <p>
           OAC + 抗血小板
          </p>
          <p>
           (n = 149)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 296)
          </p>
         </th>
         <th align="left">
          <p>
           风险比
          </p>
         </th>
         <th align="left">
          <p>
           P值
          </p>
         </th>
         <th align="left">
          <p>
           OAC + 抗血小板
          </p>
          <p>
           (n = 152.2)
          </p>
         </th>
         <th align="left">
          <p>
           OAC
          </p>
          <p>
           (n = 284.5)
          </p>
         </th>
         <th align="left">
          <p>
           风险比
          </p>
         </th>
         <th align="left">
          <p>
           P值
          </p>
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left">
          <p>
           所有复合结果
          </p>
         </td>
         <td align="left">
          <p>
           31 (20.8)
          </p>
         </td>
         <td align="left">
          <p>
           62 (20.9)
          </p>
         </td>
         <td align="left">
          <p>
           0.93 [0.60;1.45]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.750
          </p>
         </td>
         <td align="left">
          <p>
           29.6 (19.4)
          </p>
         </td>
         <td align="left">
          <p>
           60.2 (21.1)
          </p>
         </td>
         <td align="left">
          <p>
           0.91 [0.55;1.50]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.709
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           全因死亡率
          </p>
         </td>
         <td align="left">
          <p>
           13 (8.7)
          </p>
         </td>
         <td align="left">
          <p>
           37 (12.5)
          </p>
         </td>
         <td align="left">
          <p>
           0.63 [0.33;1.20]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.159
          </p>
         </td>
         <td align="left">
          <p>
           9.3 (6.1)
          </p>
         </td>
         <td align="left">
          <p>
           34.6 (12.2)
          </p>
         </td>
         <td align="left">
          <p>
           0.48 [0.23;0.98]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.045
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           心血管死亡
          </p>
         </td>
         <td align="left">
          <p>
           4 (2.7)
          </p>
         </td>
         <td align="left">
          <p>
           13 (4.4)
          </p>
         </td>
         <td align="left">
          <p>
           0.60 [0.19;1.83]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.365
          </p>
         </td>
         <td align="left">
          <p>
           2.3 (1.5)
          </p>
         </td>
         <td align="left">
          <p>
           12.1 (4.3)
          </p>
         </td>
         <td align="left">
          <p>
           0.34 [0.10;1.17]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.087
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           缺血性卒中（致命，非致命）
          </p>
         </td>
         <td align="left">
          <p>
           10 (6.7)
          </p>
         </td>
         <td align="left">
          <p>
           9 (3.0)
          </p>
         </td>
         <td align="left">
          <p>
           2.19 [0.89;5.38]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.089
          </p>
         </td>
         <td align="left">
          <p>
           13.5 (8.8)
          </p>
         </td>
         <td align="left">
          <p>
           8.9 (3.1)
          </p>
         </td>
         <td align="left">
          <p>
           2.76 [1.03;7.40]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.044
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           心肌梗死（致命，非致命）
          </p>
         </td>
         <td align="left">
          <p>
           0 (0.0)
          </p>
         </td>
         <td align="left">
          <p>
           7 (2.4)
          </p>
         </td>
         <td align="left">
          <p>
           0.00 [0.00;Inf]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.998
          </p>
         </td>
         <td align="left">
          <p>
           0.0 (0.0)
          </p>
         </td>
         <td align="left">
          <p>
           8.4 (3.0)
          </p>
         </td>
         <td align="left">
          <p>
           0.00 [0.00;0.00]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           &lt; 0.001
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           出血性卒中（致命，非致命）
          </p>
         </td>
         <td align="left">
          <p>
           3 (2.0)
          </p>
         </td>
         <td align="left">
          <p>
           1 (0.3)
          </p>
         </td>
         <td align="left">
          <p>
           5.99 [0.62;57.60]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.121
          </p>
         </td>
         <td align="left">
          <p>
           3.8 (2.5)
          </p>
         </td>
         <td align="left">
          <p>
           1.2 (0.4)
          </p>
         </td>
         <td align="left">
          <p>
           6.12 [0.61;60.91]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.123
          </p>
         </td>
        </tr>
        <tr>
         <td align="left">
          <p>
           出血（致命，非致命）
          </p>
         </td>
         <td align="left">
          <p>
           13 (8.7)
          </p>
         </td>
         <td align="left">
          <p>
           21 (7.1)
          </p>
         </td>
         <td align="left">
          <p>
           1.12 [0.55;2.27]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.760
          </p>
         </td>
         <td align="left">
          <p>
           11.9 (7.8)
          </p>
         </td>
         <td align="left">
          <p>
           21.4 (7.5)
          </p>
         </td>
         <td align="left">
          <p>
           1.01 [0.46;2.21]
          </p>
         </td>
         <td align="char" char=".">
          <p>
           0.982
          </p>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <p>
        数值以数量（%）表示发生率和风险比[95%置信区间]。仅包括随访期间每种结果的首次发生。
       </p>
       <p>
        <italic>
         Inf
        </italic>
        无限,
        <italic>
         MI
        </italic>
        心肌梗死。
       </p>
      </table-wrap-foot>
     </table-wrap>
    </p>
   </sec>
   <sec id="Sec6">
    <title>
     匹配人群的结局比较
    </title>
    <p id="Par10">
     在进行逆概率加权后，OAC组和OAC + 抗血小板组的基线特征在加权样本量上得到了良好的平衡，分别为284.5和152.2（表
     <xref ref-type="table" rid="Tab1">
      1
     </xref>
     和补充图
     <xref ref-type="supplementary-material" rid="MOESM1">
      1
     </xref>
     ）。Kaplan–Meier估计显示，综合结局在抗栓治疗方案之间没有差异。然而，与OAC + 抗血小板相比，单独使用OAC的患者在1年内的死亡风险更高（log-rank P = 0.045，图
     <xref ref-type="fig" rid="Fig3">
      3
     </xref>
     ）。Cox回归分析显示，单独使用OAC的患者在1年内的全因死亡率显著高于接受OAC + 抗血小板的患者（6.1% vs. 12.2%；风险比，0.48；95% CI 0.23–0.98；P = 0.045）。在亚组分析中，OAC + 抗血小板治疗对全因死亡率的影响总体上与基线特征无关，而抗栓类型与脑支架、冠状动脉支架或高血压之间存在相互作用（图
     <xref ref-type="fig" rid="Fig4">
      4
     </xref>
     ）。使用OAC + 抗血小板还与较低的心血管死亡风险（1.5% vs. 4.3%，P = 0.087）或心肌梗死（0% vs. 0.6%，P &lt; 0.001）相关。然而，复发性缺血性中风在接受OAC + 抗血小板的患者中更为常见（8.8% vs. 3.1%；风险比，2.76；95% CI 1.03–7.40；P = 0.044）（表
     <xref ref-type="table" rid="Tab2">
      2
     </xref>
     ），且大多数复发性缺血性中风为非致命（补充表
     <xref ref-type="supplementary-material" rid="MOESM1">
      3
     </xref>
     ）。其他预定结局，如出血性中风和出血事件，未因抗栓治疗方案而异。
     <fig id="Fig3" position="float">
      <label>
       Figure 3
      </label>
      <caption xml:lang="en">
       <p>
        Kaplan–Meier生存曲线：(
        <bold>
         A
        </bold>
        ) 综合结局，(
        <bold>
         B
        </bold>
        ) 全因死亡率，(
        <bold>
         C
        </bold>
        ) 心肌梗死，(
        <bold>
         D
        </bold>
        ) 缺血性中风，(
        <bold>
         E
        </bold>
        ) 出血性中风，和 (
        <bold>
         F
        </bold>
        ) 出血事件，按匹配人群中的抗血栓方案分类。
       </p>
      </caption>
      <graphic href="/w/ProjectMundo-Anon-106A/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig3_HTML.png" id="MO3" mime-subtype="PNG" specific-use="web"/>
     </fig>
     <fig id="Fig4" position="float">
      <label>
       Figure 4
      </label>
      <caption xml:lang="en">
       <p>
        患者的亚组分析，使用逆概率加权。每个亚组的Cox比例风险比已获得。组合表示抗血小板和抗凝剂的组合。动脉床计数定义为患者患有的动脉粥样硬化疾病的数量，包括脑动脉狭窄、CAOD、PAOD、主动脉粥样硬化和冠状动脉及脑动脉支架植入史。
        <italic>
         CAOD
        </italic>
        冠状动脉闭塞性疾病，
        <italic>
         PAOD
        </italic>
        外周动脉闭塞性疾病，
        <italic>
         CHF
        </italic>
        慢性心力衰竭，
        <italic>
         DOAC
        </italic>
        直接口服抗凝剂，
        <italic>
         NIHSS
        </italic>
        国立卫生研究院中风量表，
        <italic>
         GFR
        </italic>
        肾小球滤过率，
        <italic>
         HR
        </italic>
        危险比。
       </p>
      </caption>
      <graphic href="/w/ProjectMundo-Anon-106A/MediaObjects/10X1038_s41598-023-51013-3/41598_2023_51013_Fig4_HTML.png" id="MO4" mime-subtype="PNG" specific-use="web"/>
     </fig>
    </p>
   </sec>
  </sec>
  <sec id="Sec7" sec-type="discussion">
   <title>
    讨论
   </title>
   <p id="Par11">
    本研究调查了在NVAF和系统性动脉粥样硬化患者中，初次缺血性中风后的一年结局是否会因抗栓策略而异。尽管在原始人群中，OAC和抗血小板联合使用没有显示出有益效果，并且在匹配人群中综合结局没有差异，但逆概率加权分析显示，在患有NVAF和系统性动脉粥样硬化的患者中，OAC和抗血小板联合使用的患者全因死亡或心肌梗死的风险较低。这些趋势在各种亚组中一致观察到，除了有脑或冠状动脉支架或高血压的患者。然而，接受抗血小板治疗和OAC的患者复发性缺血性中风的风险较高。
   </p>
   <p id="Par12">
    在NVAF患者中，合并动脉粥样硬化并不少见。合并的动脉粥样硬化疾病可以在颈动脉（高达64%）、冠状动脉（17–38%）或外周动脉疾病（6.7%）中观察到
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
     <xref ref-type="bibr" rid="CR12">
      12
     </xref>
    </sup>
    。在本研究中，CAOD是最常见的动脉粥样硬化部位（63%），其次是脑动脉粥样硬化（43%）。此外，大约三分之一的患者有两个或更多动脉床的动脉粥样硬化疾病。此外，如果存在任何动脉粥样硬化疾病，心脑血管结局在房颤患者中可能会更差
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
     ,
     <xref ref-type="bibr" rid="CR13">
      13
     </xref>
     ,
     <xref ref-type="bibr" rid="CR14">
      14
     </xref>
    </sup>
    。因此，对于NVAF和系统性动脉粥样硬化患者的管理存在担忧。
   </p>
   <p id="Par13">
    考虑到NVAF患者合并动脉粥样硬化的心血管事件风险更高，需要更强效的治疗策略。目前，针对这一特定人群的最佳抗栓策略的数据有限。由于抗血小板药物可以抑制血小板聚集并在高剪切应力和高速度条件下防止血栓形成，将抗血小板药物添加到OAC中可能对患有动脉粥样硬化性疾病的患者有益。然而，对于NVAF患者，抗血小板和OAC的联合使用是具有挑战性的，因为先前的回顾性研究和后续的荟萃分析表明，抗血小板与OAC联合使用在预防缺血事件方面的益处并未明确观察到，或仅在特定情况下注意到
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    。在我们的研究中，OAC和抗血小板联合使用的有益效果在原始研究人群中未观察到，而在使用逆概率加权平衡基线特征后，这些方案在全因死亡率和心肌梗死方面的益处得到了注意。这表明患者特征或合并症可能影响药物的疗效，并且需要对可能从OAC + 抗血小板中受益的患者进行最佳选择。在此背景下，进一步研究将受益于OAC和抗血小板联合使用的人群是必要的。
   </p>
   <p id="Par14">
    然而，对于那些被处方OAC+抗血小板药物的患者，缺血性中风复发率较高，尽管在我们的研究中，随访期间OAC+抗血小板治疗的大多数复发性缺血性中风似乎并不严重或致命。这表明，与单独使用OAC相比，联合使用抗血栓方案在预防复发性缺血性中风方面的效果较差。NVAF患者的中风风险和严重程度受VKA强度或DOAC剂量的影响
    <sup>
     <xref ref-type="bibr" rid="CR15">
      15
     </xref>
     ,
     <xref ref-type="bibr" rid="CR16">
      16
     </xref>
    </sup>
    。由于担心出血风险，医生可能不愿在随访期间使用DOAC的最佳剂量或维持VKA的治疗强度，尽管我们无法调查随访期间OAC的强度。此外，考虑到心血管事件的风险随着脑狭窄负担的增加而增加，OAC与抗血小板药物的联合可能不足以预防复发性缺血性中风。这些发现表明，需要更强效的治疗方法来预防该人群中的复发性中风。例如，高血压、血脂异常和糖尿病等血管危险因素是由房颤和动脉粥样硬化疾病引起的血栓栓塞的已知决定因素，随访期间严格控制血管危险因素将有所帮助
    <sup>
     <xref ref-type="bibr" rid="CR17">
      17
     </xref>
     <xref ref-type="bibr" rid="CR18">
      18
     </xref>
     ,
     <xref ref-type="bibr" rid="CR19">
      19
     </xref>
     ,
     <xref ref-type="bibr" rid="CR20">
      20
     </xref>
    </sup>
    。
   </p>
   <p id="Par15">
    使用OAC与抗血小板药物时，出血并发症风险增加的担忧被提出
    <sup>
     <xref ref-type="bibr" rid="CR21">
      21
     </xref>
    </sup>
    。与单独使用OAC相比，OAC与抗血小板药物的同时使用增加了出血风险（尤其是在胃肠道或颅内部位）
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    。然而，在我们的研究中，尽管在OAC+抗血小板的情况下脑出血似乎较为频繁，但OAC+抗血小板与仅OAC之间的出血并发症没有显著差异。使用DOAC与抗血小板药物时，出血并发症发生的可能性较小，而不是使用VKA与抗血小板药物或使用OAC与单一而非双重抗血小板药物
    <sup>
     <xref ref-type="bibr" rid="CR22">
      22
     </xref>
     <xref ref-type="bibr" rid="CR23">
      23
     </xref>
    </sup>
    。在我们使用OAC+抗血小板药物的患者中，主要使用单一抗血小板药物，许多患者接受DOAC治疗。此外，在我们的中风中心，随访期间严格监测血管危险因素控制。这些可能与我们的发现有关。
   </p>
   <p id="Par16">
    我们的研究有几个局限性。在这项研究中，我们根据出院时的药物将研究人群分组。尽管随访期间的药物似乎在出院后得到了良好的维持，但我们无法完全评估抗血栓药物的依从性或强度。尽管使用了一种经过验证的统计方法——逆概率加权法来评估使用回顾性数据的不同治疗效果，以消除抗血栓治疗的选择偏倚，但可能还有其他我们未考虑的因素。我们仅调查了初次中风后1年的结果；因此，这一结果并不意味着长期使用OAC+抗血小板药物的任何益处。考虑到数据集来自单一中心，以及研究的回顾性性质，数据集中可能存在选择偏倚。应进行随机对照研究以消除两组之间的选择偏倚
    <sup>
     <xref ref-type="bibr" rid="CR24">
      24
     </xref>
    </sup>
    。
   </p>
  </sec>
  <sec id="Sec8" sec-type="methods">
   <title>
    方法
   </title>
   <sec id="Sec9">
    <title>
     患者
    </title>
    <p id="Par17">
     这是一项使用基于医院的观察性队列研究数据的回顾性研究（Clinicaltrials.gov NCT03510312），调查了入院于韩国首尔Severance中风中心的缺血性中风或短暂性脑缺血发作（TIA）患者的长期预后。该队列包括在2012年1月1日至2020年12月31日期间入院的急性脑梗死或TIA患者，发病时间在7天内。所有患者均接受了脑CT和/或磁共振成像以及血管造影，包括CT血管造影、磁共振血管造影或数字减影血管造影。在住院期间，所有患者都进行了广泛和彻底的评估，以确定其人口统计数据、病史、临床表现、血管危险因素和合并症。患者还接受了标准的血液测试、12导联心电图和Holter监测。几乎所有患者都被送入中风病房，并在住院期间（中位数5天；IQR 4-6天）通过心电图进行持续监测。超声心动图，包括经食道超声心动图，是常规检查，除非因患者状况或未能获得知情同意而无法进行。本研究获得了延世大学医学院伦理委员会的批准（批准号：4-2022-1098），由于研究的回顾性性质，免除了知情同意。我们研究中的所有方法均按照《赫尔辛基宣言》的原则进行。
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     临床变量
    </title>
    <p id="Par18">
     对于每位患者，收集了人口统计数据、血管危险因素和合并症，包括高血压、糖尿病、血脂异常、CAOD、PAOD和中风史。还评估了当前吸烟（过去一个月内吸烟一支或多支）和饮酒状况。中风严重程度使用美国国立卫生研究院中风量表（NIHSS）进行评估。发病前残疾定义为初次中风前改良Rankin量表（mRS）评分为2-5。中风亚型根据急性中风治疗中Org 10172试验分类进行分类
     <sup>
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
     </sup>
     。估计的肾小球滤过率使用CKD-EPI方法计算。还收集了出院时处方的他汀类药物的数据。高强度他汀治疗定义为阿托伐他汀&gt;40 mg或瑞舒伐他汀&gt;20 mg
     <sup>
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
     </sup>
     。
    </p>
    <p id="Par19">
     我们的研究人群根据出院时处方的抗血栓方案进行分层：单独使用OAC与OAC和抗血小板药物联合使用。OAC包括VKA和DOAC，包括达比加群、利伐沙班、阿哌沙班和依多沙班。抗血小板药物包括阿司匹林、氯吡格雷、西洛他唑、曲氟舒、普拉格雷、噻氯匹定和阿格雷诺克斯。
    </p>
   </sec>
   <sec id="Sec11">
    <title>
     系统性动脉粥样硬化病变
    </title>
    <p id="Par20">
     在每位患者中调查了主动脉、大脑、心脏和外周动脉的动脉粥样硬化病变的存在情况。这包括以下一种或多种动脉粥样硬化疾病：(1) 根据北美症状性颈动脉内膜切除术试验方法，颅外动脉或华法林与阿司匹林对症状性颅内疾病方法的颅内动脉，脑动脉粥样硬化狭窄超过50%；(2) 经食道超声心动图显示升主动脉或主动脉弓的主动脉粥样硬化斑块大于4毫米；(3) 既往有冠状动脉闭塞性疾病（CAOD）或外周动脉闭塞性疾病（PAOD）的病史；(4) 冠状动脉或颈动脉支架植入。为了防止将栓塞性闭塞误解为脑动脉粥样硬化，我们仅在排除梗死区域的动脉罪犯病变或脑动脉完全闭塞后才包括狭窄病变。CAOD定义为(1) 既往有心肌梗死或不稳定型心绞痛的病史，(2) 冠状动脉狭窄，无论是有症状还是无症状，均在导管冠状动脉造影或多探头冠状动脉CT上记录。PAOD的存在定义为通过超声评估或CT血管造影验证。系统性动脉粥样硬化的负担计算为包括脑动脉狭窄、CAOD、PAOD、主动脉粥样硬化斑块和冠状动脉或脑动脉支架植入史在内的动脉粥样硬化疾病的总数
     <sup>
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     。
    </p>
   </sec>
   <sec id="Sec12">
    <title>
     结局测量
    </title>
    <p id="Par21">
     在我们的卒中中心，卒中神经科医生和研究护士通过定期面对面访问或电话访谈，结合或不结合医疗记录审查，定期联系患者或其护理人员，以调查随访期间新发现的血管事件、癌症或风险因素。本研究中包括的患者在出院后3个月和1年定期随访。
    </p>
    <p id="Par22">
     当患者死亡时，我们记录日期，并在可能的情况下确定死亡原因。心血管死亡定义为因心肌梗死、心脏骤停、心力衰竭、心血管手术或卒中导致的死亡
     <sup>
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
     </sup>
     。我们还收集了卒中后1年内复发性缺血性卒中（包括短暂性脑缺血发作）、出血性卒中、心肌梗死或出血事件的发生数据，以及事件的日期。复发性缺血性卒中由卒中专家根据临床和影像学发现确定。出血性卒中包括脑内、脑室内、蛛网膜下腔和硬膜下出血。心肌梗死的定义是基于临床症状、心脏酶、电图和影像学研究（如冠状动脉造影）诊断急性心肌梗死。记录所有出血事件，包括出血性卒中、胃肠道出血、呼吸道出血和需要输血或住院的肌肉出血。致命性缺血性卒中、致命性出血性卒中、致命性心肌梗死和致命性出血事件定义为在没有其他明显死亡原因的情况下因严重相应疾病导致的死亡，由医生决定
     <sup>
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
     </sup>
     。本研究的主要结果是卒中后1年内的综合结果。我们根据用药比较了卒中后1年内的这些预定结果。
    </p>
   </sec>
   <sec id="Sec13">
    <title>
     统计分析
    </title>
    <p id="Par23">
     比较了研究参与者的基线特征。连续变量使用Mann–Whitney U检验比较，分类变量使用Pearson卡方检验比较。为了找出与OAC联合使用抗血小板药物的独立因素，选择了与OAC + 抗血小板组显著相关的变量。使用这些变量，进行多变量逻辑回归分析，最终得出每个变量的优势比。
    </p>
    <p id="Par24">
     为了调整OAC单独使用组和OAC + 抗血小板组之间基线特征的显著差异，进行了逆概率加权。使用逻辑回归估计所有入组患者的倾向评分。选择的混杂因素包括年龄较大（&gt; 75岁）、性别、高血压、糖尿病、血脂异常、当前吸烟、充血性心力衰竭、初始NIHSS评分高（&gt; 4）、估计肾小球滤过率低（
    </p>
    <p id="Par25">
     使用Kaplan–Meier生存估计和log-rank检验比较OAC单独使用组和OAC + 抗血小板组之间结果事件率的差异。使用Cox比例风险回归比较治疗组之间的结果。所有P值均为双侧。使用R版本4.0（R Core Team，奥地利维也纳）进行统计分析
     <sup>
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
     </sup>
     。逆概率加权使用“PSWeight”包进行，生存分析使用“survival”包进行
     <sup>
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ,
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
     </sup>
     。
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    致谢
   </title>
   <p>
    本研究得到了延世大学医学院的教师研究基金（6-2022-0170）和由韩国卫生福利部资助的韩国健康产业发展研究所（KHIDI）通过韩国健康技术研发项目的资助（RS-2023-00265497）。
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    作者贡献
   </title>
   <p>
    J.H. 进行了分析，撰写并修订了主要手稿。H.L.、I.H.L.、I.H.L. 和 S.H.H. 在数据准备中发挥了重要作用。J.S. 参与了数据准备和部分统计分析。H.S.N. 修订了手稿。Y.D.K. 构思了研究，监督了分析，撰写并修订了主要手稿。
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    数据可用性
   </title>
   <p>
    The data supporting the findings of this study are available from the corresponding author on reasonable request.
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar1" sec-type="COI-statement">
    <title>
     竞争利益
    </title>
    <p id="Par26">
     The authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    参考文献
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Friberg
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       High prevalence of atrial fibrillation among patients with ischemic stroke
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2014
      </year>
      <volume>
       45
      </volume>
      <fpage>
       2599
      </fpage>
      <lpage>
       2605
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2cXhsVGgsr7F
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/STROKEAHA.114.006070
      </pub-id>
      <pub-id pub-id-type="pmid">
       25034713
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lin
        </surname>
        <given-names>
         HJ
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke severity in atrial fibrillation: The Framingham study
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       1996
      </year>
      <volume>
       27
      </volume>
      <fpage>
       1760
      </fpage>
      <lpage>
       1764
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DyaK28vjvV2qsg%3D%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/01.str.27.10.1760
      </pub-id>
      <pub-id pub-id-type="pmid">
       8841325
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kleindorfer
        </surname>
        <given-names>
         DO
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2021
      </year>
      <volume>
       52
      </volume>
      <fpage>
       e364
      </fpage>
      <lpage>
       e467
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/STR.0000000000000375
      </pub-id>
      <pub-id pub-id-type="pmid">
       34024117
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Sun
        </surname>
        <given-names>
         W
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Clinical and imaging characteristics of cerebral infarction in patients with nonvalvular atrial fibrillation combined with cerebral artery stenosis
      </article-title>
      <source>
       J. Atheroscler. Thromb.
      </source>
      <year>
       2018
      </year>
      <volume>
       25
      </volume>
      <fpage>
       720
      </fpage>
      <lpage>
       732
      </lpage>
      <pub-id pub-id-type="doi">
       10.5551/jat.43240
      </pub-id>
      <pub-id pub-id-type="pmid">
       29877196
      </pub-id>
      <pub-id pub-id-type="pmcid">
       6099075
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lehtola
        </surname>
        <given-names>
         H
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke recurrence in patients with atrial fibrillation: Concomitant carotid artery stenosis doubles the risk
      </article-title>
      <source>
       Eur. J. Neurol.
      </source>
      <year>
       2017
      </year>
      <volume>
       24
      </volume>
      <fpage>
       719
      </fpage>
      <lpage>
       725
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:STN:280:DC%2BC1czosFyisw%3D%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1111/ene.13280
      </pub-id>
      <pub-id pub-id-type="pmid">
       28317289
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhou
        </surname>
        <given-names>
         G
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Cerebral arteriosclerosis stenosis predicts poor short-term prognosis in non-valvular atrial fibrillation related cardioembolic stroke treated by reperfusion therapy
      </article-title>
      <source>
       Clin. Neurol. Neurosurg.
      </source>
      <year>
       2021
      </year>
      <volume>
       207
      </volume>
      <fpage>
       106738
      </fpage>
      <pub-id pub-id-type="doi">
       10.1016/j.clineuro.2021.106738
      </pub-id>
      <pub-id pub-id-type="pmid">
       34147840
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chang
        </surname>
        <given-names>
         YJ
        </given-names>
       </name>
       <name>
        <surname>
         Ryu
        </surname>
        <given-names>
         SJ
        </given-names>
       </name>
       <name>
        <surname>
         Lin
        </surname>
        <given-names>
         SK
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation
      </article-title>
      <source>
       Cerebrovasc. Dis.
      </source>
      <year>
       2002
      </year>
      <volume>
       13
      </volume>
      <fpage>
       16
      </fpage>
      <lpage>
       20
      </lpage>
      <pub-id pub-id-type="doi">
       10.1159/000047740
      </pub-id>
      <pub-id pub-id-type="pmid">
       11810005
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Dentali
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Douketis
        </surname>
        <given-names>
         JD
        </given-names>
       </name>
       <name>
        <surname>
         Lim
        </surname>
        <given-names>
         W
        </given-names>
       </name>
       <name>
        <surname>
         Crowther
        </surname>
        <given-names>
         M
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: A meta-analysis of randomized trials
      </article-title>
      <source>
       Arch. Intern. Med.
      </source>
      <year>
       2007
      </year>
      <volume>
       167
      </volume>
      <fpage>
       117
      </fpage>
      <lpage>
       124
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2sXhvFKms7w%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1001/archinte.167.2.117
      </pub-id>
      <pub-id pub-id-type="pmid">
       17242311
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Eikelboom
        </surname>
        <given-names>
         JW
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Rivaroxaban with or without aspirin in stable cardiovascular disease
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2017
      </year>
      <volume>
       377
      </volume>
      <fpage>
       1319
      </fpage>
      <lpage>
       1330
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC2sXhs1Git7jN
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa1709118
      </pub-id>
      <pub-id pub-id-type="pmid">
       28844192
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Bonaca
        </surname>
        <given-names>
         MP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Rivaroxaban in peripheral artery disease after revascularization
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2020
      </year>
      <volume>
       382
      </volume>
      <fpage>
       1994
      </fpage>
      <lpage>
       2004
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3cXhtVeksrbI
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa2000052
      </pub-id>
      <pub-id pub-id-type="pmid">
       32222135
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chen
        </surname>
        <given-names>
         LY
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Atrial fibrillation burden: Moving beyond atrial fibrillation as a binary entity: A scientific statement from the American Heart Association
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2018
      </year>
      <volume>
       137
      </volume>
      <fpage>
       e623
      </fpage>
      <lpage>
       e644
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIR.0000000000000568
      </pub-id>
      <pub-id pub-id-type="pmid">
       29661944
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8463258
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Investigators
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study
      </article-title>
      <source>
       Am. Heart J.
      </source>
      <year>
       2002
      </year>
      <volume>
       143
      </volume>
      <fpage>
       991
      </fpage>
      <lpage>
       1001
      </lpage>
      <pub-id pub-id-type="doi">
       10.1067/mhj.2002.122875
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zhu
        </surname>
        <given-names>
         J
        </given-names>
       </name>
       <name>
        <surname>
         Tan
        </surname>
        <given-names>
         X
        </given-names>
       </name>
       <name>
        <surname>
         Zhou
        </surname>
        <given-names>
         JZ
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A systematic review and meta-analysis
      </article-title>
      <source>
       Clin. Cardiol.
      </source>
      <year>
       2021
      </year>
      <volume>
       44
      </volume>
      <fpage>
       1050
      </fpage>
      <lpage>
       1057
      </lpage>
      <pub-id pub-id-type="doi">
       10.1002/clc.23678
      </pub-id>
      <pub-id pub-id-type="pmid">
       34170015
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8364730
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hillerson
        </surname>
        <given-names>
         D
        </given-names>
       </name>
       <name>
        <surname>
         Wool
        </surname>
        <given-names>
         T
        </given-names>
       </name>
       <name>
        <surname>
         Ogunbayo
        </surname>
        <given-names>
         GO
        </given-names>
       </name>
       <name>
        <surname>
         Sorrell
        </surname>
        <given-names>
         VL
        </given-names>
       </name>
       <name>
        <surname>
         Leung
        </surname>
        <given-names>
         SW
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Incidental coronary artery calcification and stroke risk in patients with atrial fibrillation
      </article-title>
      <source>
       AJR. Am. J. Roentgenol.
      </source>
      <year>
       2020
      </year>
      <volume>
       215
      </volume>
      <fpage>
       344
      </fpage>
      <pub-id pub-id-type="doi">
       10.2214/AJR.19.22298
      </pub-id>
      <pub-id pub-id-type="pmid">
       32348185
      </pub-id>
      <pub-id pub-id-type="pmcid">
       7447556
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hylek
        </surname>
        <given-names>
         EM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2003
      </year>
      <volume>
       349
      </volume>
      <fpage>
       1019
      </fpage>
      <lpage>
       1026
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD3sXntlagtbY%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa022913
      </pub-id>
      <pub-id pub-id-type="pmid">
       12968085
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Auer
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists
      </article-title>
      <source>
       J. Neurol.
      </source>
      <year>
       2019
      </year>
      <volume>
       266
      </volume>
      <fpage>
       2263
      </fpage>
      <lpage>
       2272
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1MXhtFKhur3J
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1007/s00415-019-09412-y
      </pub-id>
      <pub-id pub-id-type="pmid">
       31165232
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Park
        </surname>
        <given-names>
         JH
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Atherosclerotic burden and vascular risk in stroke patients with atrial fibrillation
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       2021
      </year>
      <volume>
       52
      </volume>
      <fpage>
       1662
      </fpage>
      <lpage>
       1672
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXht1arsr3F
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1161/strokeaha.120.032232
      </pub-id>
      <pub-id pub-id-type="pmid">
       33794654
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kodani
        </surname>
        <given-names>
         E
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Impact of blood pressure control on thromboembolism and major hemorrhage in patients with nonvalvular atrial fibrillation: A subanalysis of the J-RHYTHM registry
      </article-title>
      <source>
       J. Am. Heart Assoc.
      </source>
      <year>
       2016
      </year>
      <volume>
       5
      </volume>
      <fpage>
       e004075
      </fpage>
      <pub-id pub-id-type="doi">
       10.1161/JAHA.116.004075
      </pub-id>
      <pub-id pub-id-type="pmid">
       27620886
      </pub-id>
      <pub-id pub-id-type="pmcid">
       5079049
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR19">
     <label>
      19.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Ding
        </surname>
        <given-names>
         WY
        </given-names>
       </name>
       <name>
        <surname>
         Protty
        </surname>
        <given-names>
         MB
        </given-names>
       </name>
       <name>
        <surname>
         Davies
        </surname>
        <given-names>
         IG
        </given-names>
       </name>
       <name>
        <surname>
         Lip
        </surname>
        <given-names>
         GYH
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Relationship between lipoproteins, thrombosis, and atrial fibrillation
      </article-title>
      <source>
       Cardiovasc. Res.
      </source>
      <year>
       2021
      </year>
      <volume>
       118
      </volume>
      <fpage>
       716
      </fpage>
      <lpage>
       731
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB38XhvVOltbnM
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/cvr/cvab017
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8859639
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR20">
     <label>
      20.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Echouffo-Tcheugui
        </surname>
        <given-names>
         JB
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Care patterns and outcomes in atrial fibrillation patients with and without diabetes
      </article-title>
      <source>
       J. Am. Coll. Cardiol.
      </source>
      <year>
       2017
      </year>
      <volume>
       70
      </volume>
      <fpage>
       1325
      </fpage>
      <lpage>
       1335
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.jacc.2017.07.755
      </pub-id>
      <pub-id pub-id-type="pmid">
       28882229
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR21">
     <label>
      21.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Best
        </surname>
        <given-names>
         JG
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Antithrombotic dilemmas in stroke medicine: New data, unsolved challenges
      </article-title>
      <source>
       J. Neurol. Neurosurg. Psychiatry
      </source>
      <year>
       2022
      </year>
      <pub-id pub-id-type="doi">
       10.1136/jnnp-2020-325249
      </pub-id>
      <pub-id pub-id-type="pmid">
       35728935
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR22">
     <label>
      22.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Douros
        </surname>
        <given-names>
         A
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Concomitant use of direct oral anticoagulants with antiplatelet agents and the risk of major bleeding in patients with nonvalvular atrial fibrillation
      </article-title>
      <source>
       Am. J. Med.
      </source>
      <year>
       2019
      </year>
      <volume>
       132
      </volume>
      <fpage>
       191
      </fpage>
      <lpage>
       199.e112
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BC1cXit1yms7rO
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/j.amjmed.2018.10.008
      </pub-id>
      <pub-id pub-id-type="pmid">
       30691551
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR23">
     <label>
      23.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Lou
        </surname>
        <given-names>
         B
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Meta-analysis comparing dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention with stent implantation
      </article-title>
      <source>
       Am. J. Cardiol.
      </source>
      <year>
       2018
      </year>
      <volume>
       122
      </volume>
      <fpage>
       604
      </fpage>
      <lpage>
       611
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.amjcard.2018.04.050
      </pub-id>
      <pub-id pub-id-type="pmid">
       30205887
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR24">
     <label>
      24.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Deb
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       A review of propensity-score methods and their use in cardiovascular research
      </article-title>
      <source>
       Can. J. Cardiol.
      </source>
      <year>
       2016
      </year>
      <volume>
       32
      </volume>
      <fpage>
       259
      </fpage>
      <lpage>
       265
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.cjca.2015.05.015
      </pub-id>
      <pub-id pub-id-type="pmid">
       26315351
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR25">
     <label>
      25.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Adams
        </surname>
        <given-names>
         HP
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment
      </article-title>
      <source>
       Stroke
      </source>
      <year>
       1993
      </year>
      <volume>
       24
      </volume>
      <fpage>
       35
      </fpage>
      <lpage>
       41
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/01.STR.24.1.35
      </pub-id>
      <pub-id pub-id-type="pmid">
       7678184
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR26">
     <label>
      26.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Grundy
        </surname>
        <given-names>
         SM
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2019
      </year>
      <volume>
       139
      </volume>
      <fpage>
       e1082
      </fpage>
      <lpage>
       e1143
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIR.0000000000000625
      </pub-id>
      <pub-id pub-id-type="pmid">
       30586774
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR27">
     <label>
      27.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <collab>
        NACET Collaborators
       </collab>
      </person-group>
      <article-title xml:lang="en">
       Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       1991
      </year>
      <volume>
       325
      </volume>
      <fpage>
       445
      </fpage>
      <lpage>
       453
      </lpage>
      <pub-id pub-id-type="doi">
       10.1056/NEJM199108153250701
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR28">
     <label>
      28.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Chimowitz
        </surname>
        <given-names>
         MI
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis
      </article-title>
      <source>
       N. Engl. J. Med.
      </source>
      <year>
       2005
      </year>
      <volume>
       352
      </volume>
      <fpage>
       1305
      </fpage>
      <lpage>
       1316
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BD2MXislCjsLo%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1056/NEJMoa043033
      </pub-id>
      <pub-id pub-id-type="pmid">
       15800226
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR29">
     <label>
      29.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Hicks
        </surname>
        <given-names>
         KA
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       2017 Cardiovascular and stroke endpoint definitions for clinical trials
      </article-title>
      <source>
       Circulation
      </source>
      <year>
       2018
      </year>
      <volume>
       137
      </volume>
      <fpage>
       961
      </fpage>
      <lpage>
       972
      </lpage>
      <pub-id pub-id-type="doi">
       10.1161/CIRCULATIONAHA.117.033502
      </pub-id>
      <pub-id pub-id-type="pmid">
       29483172
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR30">
     <label>
      30.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Crump
        </surname>
        <given-names>
         RK
        </given-names>
       </name>
       <name>
        <surname>
         Hotz
        </surname>
        <given-names>
         VJ
        </given-names>
       </name>
       <name>
        <surname>
         Imbens
        </surname>
        <given-names>
         GW
        </given-names>
       </name>
       <name>
        <surname>
         Mitnik
        </surname>
        <given-names>
         OA
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Dealing with limited overlap in estimation of average treatment effects
      </article-title>
      <source>
       Biometrika
      </source>
      <year>
       2009
      </year>
      <volume>
       96
      </volume>
      <fpage>
       187
      </fpage>
      <lpage>
       199
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       2482144
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1093/biomet/asn055
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR31">
     <label>
      31.
     </label>
     <mixed-citation publication-type="other">
      Team, R. C.
      <italic>
       R: A Language and Environment for Statistical Computing
      </italic>
      .
      <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org">
       http://www.R-project.org
      </ext-link>
      (2014).
     </mixed-citation>
    </ref>
    <ref id="CR32">
     <label>
      32.
     </label>
     <mixed-citation publication-type="book">
      <person-group person-group-type="author">
       <name>
        <surname>
         Therneau
        </surname>
        <given-names>
         TM
        </given-names>
       </name>
       <name>
        <surname>
         Grambsch
        </surname>
        <given-names>
         PM
        </given-names>
       </name>
      </person-group>
      <source>
       Modeling Survival Data: Extending the Cox Model
      </source>
      <year>
       2000
      </year>
      <publisher-name>
       Springer
      </publisher-name>
      <pub-id pub-id-type="doi">
       10.1007/978-1-4757-3294-8
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR33">
     <label>
      33.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Zeng
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         F
        </given-names>
       </name>
       <name>
        <surname>
         Wang
        </surname>
        <given-names>
         R
        </given-names>
       </name>
       <name>
        <surname>
         Li
        </surname>
        <given-names>
         F
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Propensity score weighting for covariate adjustment in randomized clinical trials
      </article-title>
      <source>
       Stat. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       40
      </volume>
      <fpage>
       842
      </fpage>
      <lpage>
       858
      </lpage>
      <pub-id assigning-authority="American Mathematical Society" pub-id-type="other">
       4201106
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1002/sim.8805
      </pub-id>
      <pub-id pub-id-type="pmid">
       33174296
      </pub-id>
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec14">
     <title>
      补充信息
     </title>
     <p id="Par27">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary Information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41598_2023_51013_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information.
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    补充信息
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41598-023-51013-3">
     https://doi.org/10.1038/s41598-023-51013-3
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <title>
    出版者声明
   </title>
   <p>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
